Phibro Animal Health (NASDAQ:PAHC) Downgraded to “C+” at TheStreet

TheStreet lowered shares of Phibro Animal Health (NASDAQ:PAHC) from a b- rating to a c+ rating in a report issued on Tuesday, TheStreetRatingsTable reports.

Several other analysts also recently weighed in on the stock. Barclays lowered their price target on shares of Phibro Animal Health from $25.00 to $18.00 and set an underweight rating for the company in a research note on Thursday, August 29th. BidaskClub downgraded shares of Phibro Animal Health from a buy rating to a hold rating in a research note on Friday, August 30th. ValuEngine downgraded shares of Phibro Animal Health from a hold rating to a sell rating in a research note on Wednesday, August 28th. Guggenheim assumed coverage on shares of Phibro Animal Health in a research note on Thursday, May 23rd. They issued a neutral rating for the company. Finally, Credit Suisse Group reissued a neutral rating and issued a $25.00 price target (down from $31.00) on shares of Phibro Animal Health in a research note on Wednesday, August 28th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $26.60.

Phibro Animal Health stock traded up $0.54 during mid-day trading on Tuesday, hitting $20.96. The company’s stock had a trading volume of 515,900 shares, compared to its average volume of 182,268. The company has a debt-to-equity ratio of 1.45, a current ratio of 3.02 and a quick ratio of 1.74. The stock has a market cap of $826.05 million, a price-to-earnings ratio of 13.70, a price-to-earnings-growth ratio of 4.09 and a beta of 0.82. The business has a 50 day moving average price of $27.76 and a 200-day moving average price of $30.30. Phibro Animal Health has a 12 month low of $20.00 and a 12 month high of $44.99.



Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Tuesday, August 27th. The company reported $0.33 earnings per share for the quarter, missing the consensus estimate of $0.34 by ($0.01). The business had revenue of $203.90 million during the quarter, compared to the consensus estimate of $206.00 million. Phibro Animal Health had a return on equity of 29.99% and a net margin of 6.59%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.46 earnings per share. On average, equities research analysts expect that Phibro Animal Health will post 1.13 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Wednesday, September 4th will be given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.29%. The ex-dividend date is Tuesday, September 3rd. Phibro Animal Health’s payout ratio is 31.37%.

In other news, Director E Thomas Corcoran acquired 5,000 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were purchased at an average price of $21.21 per share, for a total transaction of $106,050.00. Following the completion of the transaction, the director now owns 15,000 shares of the company’s stock, valued at $318,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 50.29% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC increased its position in shares of Phibro Animal Health by 73.3% in the second quarter. FNY Investment Advisers LLC now owns 1,040 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. Aperio Group LLC increased its position in shares of Phibro Animal Health by 3.5% in the second quarter. Aperio Group LLC now owns 14,585 shares of the company’s stock valued at $463,000 after acquiring an additional 500 shares during the period. Texas Permanent School Fund increased its position in shares of Phibro Animal Health by 4.1% in the first quarter. Texas Permanent School Fund now owns 13,773 shares of the company’s stock valued at $455,000 after acquiring an additional 548 shares during the period. Comerica Bank increased its position in shares of Phibro Animal Health by 2.8% in the first quarter. Comerica Bank now owns 19,961 shares of the company’s stock valued at $674,000 after acquiring an additional 550 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Phibro Animal Health by 1.0% during the first quarter. Rhumbline Advisers now owns 58,969 shares of the company’s stock valued at $1,946,000 after buying an additional 610 shares during the period. Hedge funds and other institutional investors own 51.74% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Further Reading: How Investors Use a Balance Sheet

Analyst Recommendations for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.